The results suggested that BYL719 enhanced the anti-cancer effect of gefitinib by inhibiting the p-AKT signal pathway in PI3K/AKT activation-induced gefitinib-resistance NSCLC cells. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.